Login / Signup

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

Alexander M MenziesGeorgina V LongAmiee KohnHussein A TawbiJeffrey WeberKeith FlahertyGrant A McArthurPaolo A AsciertoYanina PflugerKarl LewisKaty K TsaiOmid HamidHans PrenenLuis FeinErjian WangCarolin GuenzelFan ZhangJoseph F KlehaAlessandra di PietroMichael A Davies
Published in: Neuro-oncology advances (2024)
Despite small patient numbers due to early trial termination, BMRR appeared similar between the SLI and ph2, and the ph2 safety profile appeared consistent with previous reports of standard-dose encorafenib in combination with binimetinib.
Keyphrases